Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Non-Current Assets (2021 - 2026)

Inhibikase Therapeutics (IKT) has 6 years of Non-Current Assets data on record, last reported at $1.2 million in Q1 2026.

  • On a quarterly basis, Non-Current Assets rose 891.52% to $1.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.4 million, a 398.23% increase, with the full-year FY2025 number at $1.1 million, up 637.27% from a year prior.
  • Non-Current Assets reached $1.2 million in Q1 2026 per IKT's latest filing, up from $1.1 million in the prior quarter.
  • Over the last five years, Non-Current Assets for IKT hit a ceiling of $1.2 million in Q1 2026 and a floor of $43089.0 in Q2 2022.
  • A 5-year average of $439413.5 and a median of $312814.5 in 2023 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: tumbled 73.84% in 2025, then skyrocketed 891.52% in 2026.
  • Tracing IKT's Non-Current Assets over 5 years: stood at $565175.0 in 2022, then tumbled by 47.7% to $295599.0 in 2023, then plummeted by 49.75% to $148537.0 in 2024, then soared by 637.27% to $1.1 million in 2025, then grew by 5.54% to $1.2 million in 2026.
  • Business Quant data shows Non-Current Assets for IKT at $1.2 million in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.